Back to Directory Cheryl Jennings Email cheryl_jennings@rush.edu Institution Northwestern University CRS Title Laboratory Manager Request an Update Affiliated Studies IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Adults with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Pending IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in People with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status In Development IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling IMPAACT 2039: EXCEED DAIDS Number 38,988 Research Area Cure and Immunotherapy Study Status In Development P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure and Immunotherapy Study Status Enrolling Show All
IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Adults with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Pending
IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in People with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status In Development
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling
IMPAACT 2039: EXCEED DAIDS Number 38,988 Research Area Cure and Immunotherapy Study Status In Development
P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure and Immunotherapy Study Status Enrolling
